LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
Liquidia has surged 129.7% so far in 2026 as Yutrepia gains traction, driving strong sales, profitability and higher earnings estimates.
LQDA - Liquidia Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$74.83
DETAILS
HIGH:
$109.00
LOW:
$60.00
MEDIAN:
$71.50
CONSENSUS:
$74.83
DOWNSIDE:
8.13%
Stock News
Liquidia Corporation (LQDA) Is Up 9.99% in One Week: What You Should Know
Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Yutrepia Maintain Momentum for LQDA Stock in 2026?
LQDA's Yutrepia launch is gaining traction, with $130 million in Q1 sales, rising prescriptions and profitability as the company expands in PAH.
This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
3 Best Low-Beta Stocks to Buy Right Away: LQDA, FLXS & AGX
LQDA, FLXS and AGX screen as low-beta stocks with positive price moves, solid trading volume and company-specific growth drivers amid market fears.
Liquidia Corporation (LQDA) Shareholder/Analyst Call Prepared Remarks Transcript
Liquidia Corporation (LQDA) Shareholder/Analyst Call Prepared Remarks Transcript
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.
Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
MORRISVILLE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that the company will present four posters at the PHA 2026 International PH Conference and Scientific Sessions taking place June 11-14 in Dallas.
Liquidia Corp (LQDA) Stock Up 3.4% and Still Undervalued -- GF Score: 75/100
On June 08, 2026, Liquidia Corp (LQDA) shares rose 3.4% today, continuing a strong performance within a 52-week range of $11.85 to $66.78. The stock has shown i
Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index
MORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026.
4 Best Low-Beta Stocks to Buy Right Away: LQDA, CVX, OXY & VLO
Fragile Iran ceasefire keeps stocks volatile. Low-beta picks LQDA, CVX, OXY and VLO show recent gains and solid volume.
4 Biotech Stocks Investors Should Watch in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
Are You Looking for a Top Momentum Pick? Why Liquidia Corporation (LQDA) is a Great Choice
Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company's business in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45 p.m.
4 Low-Beta Stocks for a Steadier Portfolio: LQDA, XOM, VLO & FANG
Middle East tensions are stoking volatility; a low-beta screen spotlights Liquidia, Exxon Mobil, Valero Energy and Diamondback Energy.
Earnings Estimates Moving Higher for Liquidia Corporation (LQDA): Time to Buy?
Liquidia Corporation (LQDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
What to Know About This Fund’s $15.5 Million Sale of Liquidia as Shares Skyrocket Nearly 260%
Liquidia develops therapies for rare cardiopulmonary diseases, leveraging proprietary drug delivery technologies in the U.S. market.
Price Targets
Liquidia price target raised to $109 from $59 at BTIG
$109.00
(was $71.07)
BTIG
Liquidia price target raised to $75 from $67 at H.C. Wainwright
$75.00
(was $62.54)
H.C. Wainwright
Liquidia Technologies (LQDA) PT Raised to $75 at H.C. Wainwright
$75.00
(was $62.54)
Oppenheimer
Liquidia Technologies (LQDA) PT Raised to $75 at H.C. Wainwright
$28.00
(was $62.54)
H.C. Wainwright
Raymond James sees positive readthrough for Liquidia from Hikma v. Amarin
$68.00
(was $62.54)
Raymond James
Liquidia price target raised to $67 from $55 at H.C. Wainwright
$67.00
(was $53.50)
Andrew Fein
·
H.C. Wainwright
Liquidia price target raised to $62 from $51 at Wells Fargo
$62.00
(was $53.13)
Wells Fargo
Liquidia price target raised to $60 from $57 at Jefferies
$60.00
(was $53.13)
Amy Li
·
Jefferies
Liquidia price target raised to $55 from $45 at Jefferies
$55.00
(was $37.02)
Amy Li
·
Jefferies
Liquidia price target raised to $50 from $35 at H.C. Wainwright
$50.00
(was $27.32)
H.C. Wainwright
Liquidia Technologies (LQDA) PT Raised to $47 at Raymond James
$47.00
(was $25.22)
Ryan Deschner
·
Raymond James
Liquidia price target raised to $45 from $43 at Jefferies
$45.00
(was $25.22)
Jefferies
Liquidia downgraded to Underperform from Perform at Oppenheimer
$13.00
(was $17.03)
Andreas Argyrides
·
Oppenheimer
Liquidia price target raised to $36 from $34 at Scotiabank
$36.00
(was $16.12)
Greg Harrison
·
Scotiabank
Liquidia price target raised to $34 from $30 at Scotiabank
$34.00
(was $15.44)
Greg Harrison
·
Scotiabank
Liquidia named a top pick for 2025 at Needham
$19.00
(was $12.40)
Serge Belanger
·
Needham
Liquidia price target lowered to $23 from $24 at BofA
$23.00
(was $9.79)
Jason Gerberry
·
Bank of America Securities
Liquidia price target lowered to $17 from $22 at Jefferies
$17.00
(was $9.59)
Kambiz Yazdi
·
Jefferies
Liquidia upgraded to Strong Buy from Outperform at Raymond James
$27.00
(was $9.82)
Strong Buy
·
Raymond James
Liquidia Technologies (LQDA) PT Lowered to $23 at Jefferies
$23.00
(was $11.96)
Kambiz Yazdi
·
Jefferies